NT 10-K Late Filing Notice for Mosaic ImmunoEngineering Inc.

NT 10-K 1 mosaic_ext.htm NOTICE OF LATE FILING UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON D.C. 20549

---

FORM 12b-25

NOTIFICATION OF LATE FILING

| (Check One): | ☒  Form 10-K | ☐  Form 20-F | ☐  Form 11-K | ☐  Form N-CSR |
| | ☐  Form 10-Q | ☐  Form 10-D | ☐  Form N-CEN | |

For Period Ended: December 31, 2025

| ☐  Transition Report on Form 10-K | | ☐  Transition Report on Form 20-F |
| ☐  Transition Report on Form 11-K | | ☐  Transition Report on Form 10-Q |

For the Transition Period Ended: ________________________

| Read Instruction (on back page) Before Preparing
Form. Please Print or Type.

Nothing in this form shall be construed to imply
that the Commission has verified any information contained herein. |

If the notification relates to a portion of the
filing checked above, identify the Item(s) to which the notification relates:

PART I - REGISTRANT INFORMATION

Mosaic ImmunoEngineering, Inc.

Full Name of Registrant:

Former Name if Applicable

9114 Adams Avenue, #202

Address of Principal Executive Office (Street and Number)

Huntington Beach, CA 92646

City, State, Zip Code

| | | |

PART II - RULES 12b-25 (b) AND (c)

If the subject report could not be filed without
unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box
if appropriate)

| | (a) | The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
| ☒ | (b) | The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and |
| | (c) | The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |

PART III - NARRATIVE

State below in reasonable detail the reasons why
Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof could not be filed within the prescribed
time period.

Mosaic ImmunoEngineering, Inc., a Delaware corporation
(the “Company”), was unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the fiscal
year ended December 31, 2025 (the “Form 10-K”) by the prescribed deadline because additional time, resources and effort are
required to complete work related to the Company’s financial reporting and close procedures. The Company expects to file its Form
10-K as soon as possible, but no later than the fifteenth calendar day following the prescribed due date of the Form 10-K.

PART IV - OTHER INFORMATION

(1) Name and telephone number of person to contact
in regard to this notification:

| Steven King | | 657 | | 208-0890 |
| (Name) | | (Area Code) | | (Telephone No.) |

(2) Have all other periodic reports required under
section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12
months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s). ☒ Yes ☐ No

(3) Is it anticipated that any significant change
in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included
in the subject report or portion thereof? ☐ Yes ☒ No

If so, attach an explanation of the anticipated
change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be
made.

| | 2 | |

Mosaic ImmunoEngineering, Inc.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.

| Date: | March 31, 2026 | By: | /s/  Steven King

Title President and CEO |

| | 3 | |